← Back to Search

Cannabinoid Therapy

Medical Cannabis for Chronic Pain

Minneapolis, MN
N/A
Waitlist Available
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal or corrected-to-normal vision and hearing
Be older than 18 years old
Must not have
Degenerative neurological condition or neurological condition impacting brain function (e.g., epilepsy)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at baseline and after four months
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how medical cannabis affects cognitive function and brain activity in chronic pain patients. They will compare the effects of CBD-dominant and THC-dominant products and track participants over four months

See full description
Who is the study for?
This trial is for adults aged 35-65 with chronic pain, prioritizing those with orthopedic issues. Participants must be new medical cannabis users or non-users, able to perform tasks and communicate by phone. They should not have a history of substance abuse or severe psychiatric conditions, and cannot be pregnant or recent mothers.Check my eligibility
What is being tested?
The study tests how different cannabis compounds (CBD vs THC) affect cognition and brain function in chronic pain patients using medical cannabis. It involves initial assessments, monthly check-ins, and follow-up testing including fMRI scans and cognitive evaluations over four months.See study design
What are the potential side effects?
While the study itself may not directly cause side effects, participants' use of medical cannabis could lead to changes in attention, memory impairment, altered brain function or connectivity which will be monitored through various neurocognitive tests.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My vision and hearing are normal, or corrected to be normal.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a brain condition like epilepsy.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~administered at baseline and after four months
This trial's timeline: 3 weeks for screening, Varies for treatment, and administered at baseline and after four months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood levels of cannabinoid compounds
CANTAB Self-Ordered Search Task
CANTAB Spatial Paired Associates Learning Task
+16 more
Secondary study objectives
Alcohol Use Disorders Identification Test (AUDIT)
Beck Depression Inventory (BDI)
Brief Pain Inventory
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental cognitive and fMRI-based tasksExperimental Treatment3 Interventions
One primary aim of this study is to examine cognitive functioning in individuals who use medical cannabis. All participants in the study will complete cognitive measures that include measures of attention, learning, memory and executive function. All participants will complete task fMRI-based measures of learning and inhibitory control. NIH considers the cognitive and fMRI tasks to be interventions. The fMRI learning task measures face-name associative learning. The fMRI inhibitory control task is a go/no-go task whereby participants respond on some trials to "go" stimuli and withhold responses on other trials to "no-go" stimuli. Brain activations are measured in response to each task. Each participant will complete two cognitive testing sessions as well as two fMRI sessions during the course of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive testing
2018
N/A
~450

Find a Location

Closest Location:University of Minnesota· Minneapolis, MN

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,456 Previous Clinical Trials
1,624,984 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,651 Previous Clinical Trials
3,408,554 Total Patients Enrolled
~120 spots leftby May 2029